Transcranial Direct Current Stimulation May Improve Cognitive-Motor Function in Functionally Limited Older Adults

Brad Manor, PhD¹,²,³, Junhong Zhou, PhD¹,²,³, Rachel Harrison¹,⁴, On-Yee Lo, PhD¹,²,³, Thomas G. Travison, PhD¹,²,³, Jeffrey M. Hausdorff, PhD⁴,⁵,⁶, Alvaro Pascual-Leone, MD, PhD²,³,⁷, and Lewis Lipsitz, MD¹,²,³

Abstract

Objective. To determine the effects of a transcranial direct current stimulation (tDCS) intervention with the anode placed over the left dorsolateral prefrontal cortex (dIPFC) and cathode over the right supraorbital region, on cognition, mobility, and “dual-task” standing and walking in older adults with mild-to-moderate motor and cognitive impairments. Methods. A double-blinded, block-randomized, sham-controlled trial was conducted in 18 nondemented, ambulatory adults aged ≥65 years with slow walking speed (≤1.0 m/s) and “executive” dysfunction (Trail Making Test B score ≤25th percentile of age- and education-matched norms). Interventions included ten 20-minute sessions of tDCS or sham stimulation. Cognition, mobility, and dual-task standing and walking were assessed at baseline, postintervention, and 2 weeks thereafter. Dual tasking was also assessed immediately before and after the first tDCS session. Results. Intervention compliance was high (mean ± SD = 9.5 ± 1.1 sessions) and no unexpected or serious side effects were reported. tDCS, compared with sham, induced improvements in the Montreal Cognitive Assessment total score (P = .03) and specifically within the executive function subscore of this test (P = .002), and in several metrics of dual-task standing and walking (P < .05). Each of these effects persisted for 2 weeks. tDCS had no effect on the Timed Up-and-Go test of mobility or the Geriatric Depression Scale. Those participants who exhibited larger improvements in dual-task standing posture following the first tDCS session exhibited larger cognitive-motor improvements following 2 weeks of tDCS (P < .04). Interpretation. tDCS intervention designed to stimulate the left dorsolateral prefrontal cortex may improve executive function and dual tasking in older adults with functional limitations.

Keywords
tDCS, executive function, dual-task standing, older adults

Introduction

Aging is often associated with concomitant declines in cognitive and motor function.¹,² Standing and walking are cognitive-motor tasks essential to mobility and foundational to most daily activities. Moreover, these tasks are often completed while performing other activities, for example talking, reading signs, or making decisions. Such “dual tasking” interferes with performance on one or both tasks.³,⁴ This interference, or “cost,” increases with advancing age,⁵,⁶ is exaggerated in those with cognitive “executive” dysfunction,⁷,⁸ and is predictive of future cognitive decline⁹ and falls.¹⁰,¹¹ Neuroimaging indicates that many cognitive-motor tasks, including standing and walking under dual-task conditions,¹²,¹³ activate distributed cortical networks that include the left dorsolateral prefrontal cortex (dIPFC)—a brain region subserving executive

¹Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA, USA
²Beth Israel Deaconess Medical Center, Boston, MA, USA
³Harvard Medical School, Boston, MA, USA
⁴Center for the Study of Movement, Cognition, and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
⁵Sagol School of Neuroscience and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁶Rush University Medical Center; Chicago, IL, USA
⁷Universitat Autonoma de Barcelona, Barcelona, Spain

Corresponding Author:
Brad Manor, Institute for Aging Research, Hebrew SeniorLife, 1200 Centre Street, Roslindale, MA 02131, USA.
Email: bradmanor@hsl.harvard.edu
function. We thus contend that interventions designed to facilitate functional activation of the dlPFC and its connected neural networks may improve dual-task performance, and thereby improve cognitive function and mobility in older adults.

Transcranial direct current stimulation (tDCS) offers a noninvasive and safe means of modulating cortical excitability. In healthy adults, one 20-minute session of tDCS with the anode over the left dlPFC and the cathode of the right supraorbital region facilitates the excitability of this region, enhances performance on tests of executive functions, and may improve the ability to perform two cognitive tasks concurrently. Our team has demonstrated that in both younger and older adults, one session of this type of tDCS improves performance in tests of mobility and reduces the dual-task costs to gait and postural control, when tested immediately following stimulation. Repeated exposure to tDCS also induces longer lasting increases in corticospinal excitability and cerebral perfusion, and has been reported to enhance processing speed and working memory in older adults with mild cognitive impairment. We therefore hypothesized that a multisession tDCS intervention with the anode over the left dlPFC and the cathode of the right supraorbital region, as compared to sham intervention, would induce lasting improvements in dual-task performance, cognition, and mobility, in older adults with mild-to-moderate impairments in cognitive and motor function.

Methods

Trial Design

A pilot, sham-controlled, double-blinded, block-randomized trial was conducted (NCT02436915). Participants completed a baseline assessment and were then randomized to receive a 2-week tDCS or sham intervention. Follow-up assessments were completed postintervention (ie, 2-3 days following) and again 2 weeks later. On the first day of the intervention, participants completed a dual-task standing and walking assessment before and after tDCS administration to further establish the immediate effects of tDCS on related outcomes, and to assess the potential predictive value of the acute effect of a single session of tDCS on the longer term, cumulative effects of multiple tDCS sessions.

Participants

Men and women were recruited between 2014 and 2016 via local advertisements and letters to individuals identified via medical record review at Hebrew SeniorLife and the Beth Israel Deaconess Medical Center, both in Boston, Massachusetts. Potentially eligible individuals, as determined via phone screen, completed an in-person screen. Written informed consent was obtained at the beginning of this visit. The study and all recruitment material was approved by the Hebrew SeniorLife Institutional Review Board.

Individuals were enrolled if they were aged ≥65 years and exhibited both slow gait defined by preferred 4 m over-ground walking speed less than 1.0 m/s and executive dysfunction defined by a Trail Making Test (TMT) B time below the 25th percentile of age- and education-based norms. TMT Part A required participants to connect numbered circles in sequential order as quickly as possible. Part B required participants to connect circles containing numbers or letters in alternating sequence. Participants were given up to 300 seconds to complete each part. If the participant was unable to complete the test in the allotted time, 300 seconds was used for analysis.

Exclusion criteria included an inability to ambulate without assistance from another person (canes or walkers allowed); a clinical history of stroke, Parkinson’s disease, normal pressure hydrocephalus, or other neurological condition; self-report of severe lower extremity arthritis or physician-diagnosis of peripheral neuropathy; moderate-to-severe dementia defined by a Mini Mental State Exam (MMSE) score of 18 or lower; contraindications to tDCS, including use of neuroactive drugs, self-report of seizure within the past 2 years, or open wounds on the scalp; severe depressive symptoms defined by score greater than 11 on the Geriatric Depression Scale (GDS) short form; self-report of physician-diagnosed schizophrenia, bipolar disorder, or other psychiatric illness.

Nineteen of 201 screened individuals were interested and eligible (Figure 1). Eighteen of 19 randomized participants completed the intervention. One participant withdrew from the sham intervention prior to follow-up. Reason for withdrawal was illness deemed unrelated to participation. No participants withdrew from the tDCS intervention.

Interventions

Participants had an equal chance of being assigned to the tDCS or sham intervention. tDCS was delivered with the Starstim system (Neuroelectrics Inc, Barcelona, Spain) connected to saline-soaked 35 cm² synthetic sponge electrodes placed on the scalp. The anode (ie, positive electrode) was placed over the F3 region of the 10-20 electroencephalography electrode placement guide and the cathode (ie, negative electrode) was placed over the right supra-orbital margin (Fp2) (Figure 2). This “montage” improves dual-task standing and walking when tested immediately after stimulation in younger and older adults. tDCS consisted of 20 minutes of continuous stimulation at a maximum intensity of 2.0 mA. At the beginning of stimulation, current was automatically increased from 0.1 mA, in 0.1-mA increments over 60 seconds to minimize discomfort at
During the first session, participants were instructed to notify the study personnel if and when they felt any uncomfortable sensations. The ramp-up procedure was stopped and for the remainder of this session and all sessions thereafter, tDCS was delivered at an intensity of 0.1 mA below the highest level reached. At the end of each session, current was automatically ramped down to 0.0 mA over 60 seconds. For sham stimulation, the same electrode montage, ramp-up, and session duration were used; however, current was automatically ramped down 60 seconds after ramp-up. This procedure was chosen because cutaneous sensations arising from tDCS diminish considerably within the first minute of stimulation. Participants and research staff administering tDCS were blinded to participant group assignment. Participants were assigned a code linked to their assigned intervention, as developed by the study statistician. Personnel uninvolved in tDCS administration preconfigured the tDCS and sham stimulation parameters for each code within the Starstim software. tDCS administrators were blinded to this code. Two separate codes were used for each condition to help ensure staff blinding. A “blinded” mode was then used such that tDCS parameters for each session were delivered by selecting the participant’s assigned code. At the end of the first tDCS session and every other session thereafter, participants completed a side effects questionnaire. A blinding efficacy questionnaire was completed after the final tDCS session. Participants were asked to state whether they believed they received the tDCS or sham intervention and their confidence in this belief on a scale of 0 to 10, with 10 reflecting greatest confidence.

Baseline and Follow-up Assessments

Cognition, mobility, and dual-task performance were assessed at baseline, postintervention, and again 2 weeks
later. During the first visit, individuals completed screening tests to determine eligibility, including the MMSE, \(^{25}\) 15-item short-form GDS, \(^{28}\) 4-m walk test, \(^{35}\) and TMT Parts A and B. \(^{26}\) Eligible participants then completed the Montreal Cognitive Assessment (MoCA), the Timed Up-and-Go (TUG) test of mobility, and a dual-task paradigm. Follow-up testing included all of the above tests except the MMSE. If a cane or walker was used for any test, the participant used the same device for all similar trials at baseline and at each follow-up assessment.

The MoCA is a 30-point test of cognitive function that assesses visuospatial executive function, naming, attention, language, abstraction, delayed recall, and orientation. \(^{36}\) A different, validated version of the MoCA was used at each of the three assessments to minimize learning effects. \(^{37}\) Version order was randomized across participants. The TUG test was completed twice at each assessment and included rising from a chair, walking 3 m, turning around, and returning to a seated position. \(^{38}\)

The dual-task assessment consisted of 3 trials in each of the following conditions: (a) single-task standing, (a) dual-task standing, (c) single-task walking, and (d) dual-task walking. Within dual-task trials, participants were asked to stand or walk while audibly counting backward by 3s from a random 3-digit number between 200 and 999 provided prior to the trial. Trial order was randomized and no instructions were given regarding task prioritization. Serial subtraction was chosen because it induces meaningful dual-task costs to gait and postural control, \(^{39}\) activates a distributed cortical network, including the left dlPFC, \(^{40}\) is one of the most widely used dual-task paradigms, \(^{4}\) and is reliable and minimally influenced by learning. \(^{41}\)

Each 60-second standing trial was completed on a force plate (Model 9286AA, Kistler Instrument Corp, Amherst, NY) with eyes open, arms at side, and feet shoulder-width apart. Foot placement was traced on the first trial and this tracing was used in all subsequent trials. Before each trial, participants were reminded to stand as still as possible and focus their vision on a small “X” drawn on a wall at eye-level approximately 3 m away. Walking trials were completed on a 60-foot oval indoor track with a 14-foot GaitRite mat (Franklin, NJ) along one side. Participants began each trial just prior to the gait mat and walked approximately 1.25 times around the track so as to pass over the mat 2 separate times. Participants were reminded to walk at their preferred speed and wore the same pair of their own shoes for all trials.

For each standing trial, transverse-plane postural sway (ie, center-of-pressure) data were recorded by the force plate at 240 Hz and filtered with a 10 Hz low-pass Butterworth filter. For each walking trial, heel-strike and toe-off events were recorded (100 Hz) by the GaitRite mat.

**Study Outcomes**

The 4 primary outcomes focused on global cognitive function measured by the MoCA total score (a), mobility measured by TUG time (b), and dual task performance defined by the cost (ie, percentage decrement in performance between single and dual task conditions) to both standing postural sway speed (c) and walking speed (d). Sway speed was defined as center-of-pressure path length divided by trial duration. Walking speed was determined by calculating the distance traveled from the first heel strike to the last
toe-off on the GaitRite mat and dividing by elapsed time. For each trial, walking speed was calculated separately for each pass over the mat and then averaged. Each outcome was averaged across all trials of similar condition.

Secondary outcomes included (a) executive function defined as TMT Part B minus Part A, which adjusts the test for the motor speed and dexterity of the participant; (b) the dual-task cost to standing postural sway area (the area of an ellipse enclosing 95% of the center-of-pressure path); (c) the dual-task cost to stride time (the average time between consecutive right heel strikes); (d) the dual-task cost to stride time variability (stride time coefficient of variation); (e) postural control and gait outcomes in each condition separately; and (f) the GDS total score.

Statistical Analysis

Analyses were performed on data from the 18 participants who completed the intervention. Each of these participants completed both follow-up assessments. Analyses were performed using JMP software version 13 (SAS Institute, Cary, NC). Type I error rate for this study was set at \( \alpha = .05 \) for all tests. Descriptive statistics were used to summarize intervention group characteristics and study outcomes. Potential between-group differences in demographics and baseline characteristics were assessed by unpaired \( t \) tests. Blinding efficacy was determined using Fisher’s exact test, which determined whether participants’ guesses of tDCS condition (after 10 sessions of tDCS) were correct to a greater degree than that expected because of chance.

The effect of the 10-session tDCS intervention on each study outcome was analyzed with a separate 2-way repeated-measures analysis of variance (ANOVA). Dependent variables were the percent change in each outcome from baseline to each follow-up visit. Model effects included intervention (tDCS, sham), follow-up visit (postintervention, 2-week retention) and their interaction. Models were adjusted for age and sex. Tukey’s post hoc testing was used to compare factor means of significant models. Effect sizes were calculated using Cohen’s \( d \), with values greater than 0.8 taken to reflect large effects.

Observed effects of the tDCS intervention on study outcomes spurred 2 exploratory analyses. First, the effects of intervention on MoCA subscores were examined using separate ANOVA models similar to those described above. Second, linear regression was used to examine the relationships between (a) MoCA scores and dual-task performance at baseline across the entire cohort and (b) the percent change in each outcome following intervention specifically within the tDCS group. In the latter analysis, we used percent change data from baseline to the postintervention and 2-week retention visits, and included follow-up visit as a model effect.

The immediate effects of the first tDCS session on dual task standing and walking performance were also analyzed using 1-way ANOVAs. Dependent variables included the percent change from pre- to post-tDCS in the dual-task cost to each standing postural control and gait outcome. Models were adjusted for age and sex. Secondary models examined the effects of tDCS on postural control and gait outcomes derived separately from single- and dual-task conditions. Finally, we used Pearson correlation to quantify the degree to which immediate effects of one tDCS session were associated with the longer-term effects of the multisession tDCS intervention. These models were limited to data from those receiving tDCS and to those outcomes for which a single session of tDCS had a significant pre-post effect.

Results

Baseline Participant Characteristics

The tDCS and sham intervention groups were similar in sex distribution, age, and body mass index (BMI) (tDCS: 5 females, mean ± SD age = 82 ± 4 years, BMI = 29 ± 2 kg/m²; Sham: 5 females, age = 79 ± 4 years, BMI = 31 ± 2 kg/m²). Groups were also comparable in baseline performance in each study outcome (\( P > .05 \); Table 1). The current cohort had mild-to-moderate functional impairments; as compared to published means from healthy cohorts of similar age, average TMT B – TMT A times were approximately 100 seconds longer. TUG times were approximately 8 seconds longer, and walking speeds were approximately 0.4 m/s slower.

Intervention Compliance, Side Effects, and Blinding Efficacy

Intervention compliance was excellent (mean ± SD = 9.5 ± 1.1 of 10 sessions; range = 6-10 sessions) and similar between arms. Average intensity of tDCS did not differ between arm (tDCS: 1.9 ± 0.3 mA, range = 1.7-2.0 mA; Sham: 2.0 ± 0.1 mA, range = 1.8-2.0 mA). All side effects were mild and temporary (Table 2). One participant experienced an unrelated noninjurious fall during the intervention and no other adverse events were reported. The percentage of individuals who correctly guessed intervention assignment following intervention was 67% for those receiving tDCS and 33% for those receiving sham. This distribution did not differ between arm or from that expected by chance (Fisher’s exact test \( P = .39 \)). Confidence in these guesses was also similar between arms (tDCS = 6.2 ± 2.8 on a 10-point scale; sham = 6.6 ± 1.8; \( P = .76 \)).

Effects of the 10-Session tDCS Intervention

tDCS improved multiple aspects of cognitive and motor performance. ANOVA models adjusted for age and sex revealed a main effect of intervention on the percent change...
in MoCA total score ($F = 5.0, P = .03$, Cohen’s $d = 0.84$) (Table 1 and Figure 3). Those receiving real tDCS, compared with sham, exhibited greater increases in MoCA performance. No main effect of follow-up visit was observed, indicating that the intervention effect on MoCA performance did not differ in magnitude between the postintervention and 2-week follow-up visits. A similar intervention effect was present for the absolute change in MoCA total score ($F = 4.3, P = .04$, Cohen’s $d = 0.81$). The increase in MoCA score following tDCS was $1.7 \pm 2.7$ points postintervention and $1.8 \pm 2.9$ points at 2 weeks. The absolute change in MoCA score following sham was $0.0 \pm 2.0$ points postintervention and $0.1 \pm 1.9$ at 2 weeks.

Analysis of MoCA subscores revealed that tDCS improved performance significantly only within the visuospatial-executive function domain ($F = 11.9, P = .002$, Cohen’s $d = 1.05$; absolute change: $F = 12.1, P = .002$, Cohen’s $d = 1.05$). The absolute increase in this subscore (out of 5 possible points) following tDCS was $0.8 \pm 0.4$ points postintervention and $1.1 \pm 0.6$ points at 2 weeks. The absolute change in this subscore following sham was $-0.2 \pm 0.5$ postintervention and $-0.2 \pm 0.4$ at 2 weeks. The magnitude of intervention effect did not differ across follow-up visits. All other MoCA subscores were unchanged.

The tDCS intervention also mitigated dual-task costs to standing postural sway. Intervention effects were present

---

**Table 1. Baseline Function and the Percent Change in Functional Outcomes Following a 2-Week, 10-Session tDCS Intervention.**

<table>
<thead>
<tr>
<th></th>
<th>tDCS</th>
<th>Sham</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Percent Change From Baseline:</td>
<td>Percent Change From Baseline:</td>
</tr>
<tr>
<td></td>
<td>Postintervention</td>
<td>2 Weeks</td>
</tr>
<tr>
<td><strong>Cognition</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MoCA (total score)</td>
<td>22 ± 4</td>
<td>8 ± 17</td>
</tr>
<tr>
<td>TMT (Part B − Part A)</td>
<td>153 ± 111</td>
<td>-65 ± 25</td>
</tr>
<tr>
<td><strong>Mobility</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUG (s)</td>
<td>17 ± 6</td>
<td>-3 ± 17</td>
</tr>
<tr>
<td>4-m walk (m/s)</td>
<td>0.7 ± 0.2</td>
<td>11 ± 23</td>
</tr>
<tr>
<td><strong>Dual-task performance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standing postural sway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speed (mm/s)</td>
<td>27 ± 11</td>
<td>0 ± 18</td>
</tr>
<tr>
<td>Area (mm$^2$)</td>
<td>719 ± 242</td>
<td>-3 ± 53</td>
</tr>
<tr>
<td><strong>Walking</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single task</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speed (m/s)</td>
<td>0.7 ± 0.2</td>
<td>3 ± 11</td>
</tr>
<tr>
<td>Stride time (s)</td>
<td>1.3 ± 0.2</td>
<td>-4 ± 8</td>
</tr>
<tr>
<td>Variability (COV)</td>
<td>6.7 ± 2.0</td>
<td>-16 ± 16</td>
</tr>
<tr>
<td>Dual task (m/s)</td>
<td>0.5 ± 0.3</td>
<td>18 ± 17</td>
</tr>
<tr>
<td>Stride time (s)</td>
<td>1.6 ± 0.7</td>
<td>-8 ± 9</td>
</tr>
<tr>
<td>Variability (COV)</td>
<td>9.8 ± 2.9</td>
<td>-20 ± 15</td>
</tr>
<tr>
<td>Dual-task cost (%)</td>
<td>-28 ± 19</td>
<td>15 ± 17</td>
</tr>
<tr>
<td>Stride time (s)</td>
<td>24 ± 11</td>
<td>-24 ± 42</td>
</tr>
<tr>
<td>Variability (COV)</td>
<td>46 ± 52</td>
<td>-5 ± 67</td>
</tr>
</tbody>
</table>

Abbreviations: tDCS, transcranial direct current stimulation; MoCA, Montreal Cognitive Assessment; TMT, Trail Making Test; TUG, Timed Up-and-Go; COV, coefficient of variation about average stride time.

Values indicate mean and standard deviation. Percent change mean values with a significant intervention main effect ($P \leq .05$) are in boldface.

$^bP$ values are for the main effect of intervention on the percent change in each outcome from baseline to follow-up within 2-way repeated-measures analyses of variance adjusted for age and sex.
for the percent change in dual-task costs to sway speed ($F = 10.6, P = .004$, Cohen’s $d = 1.12$) and area ($F = 29.6, P < .0001$, Cohen’s $d = 1.40$) (Table 1). For each outcome, tDCS induced greater percent reductions from baseline as compared with sham, and the magnitude of observed reductions did not differ between the 2 follow-up visits.

Further analysis revealed that neither tDCS nor sham intervention influenced postural sway when standing quietly. In contrast, intervention effects were observed for dual-task postural sway speed ($F = 8.1, P < .001$, Cohen’s $d = 1.01$) and area ($F = 10.8, P = .003$, Cohen’s $d = 1.12$) (Table 1). The tDCS intervention, as compared with sham, induced greater reductions to both outcomes, and the magnitude of these reductions did not differ between the 2 follow-up visits.

The tDCS intervention improved several markers of gait, specifically when dual tasking. Significant intervention effects were observed for dual-task stride time ($F = 4.3, P = .05$, Cohen’s $d = 0.99$) and dual-task stride time variability ($F = 6.1, P = .02$, Cohen’s $d = 0.99$) (Table 1). Again, tDCS induced greater reductions in these outcomes, compared with sham, and the magnitude of these reductions did not differ between follow-up visits. tDCS influenced neither gait outcomes within single-task conditions nor the dual task costs to these outcomes.

tDCS did not affect mobility as measured by the TUG test, depressive systems as measured by the GDS, or executive function as measured by TMT B. With regard to TMT, both intervention arms exhibited large performance improvements over the follow-up period as compared with baseline.

### Relationships Between MoCA and Dual-Task Performance

Across all participants at baseline, those with worse MoCA performance (lower total scores) exhibited higher dual task costs to postural sway area ($r^2 = 0.34, P = .02$). In the tDCS group, the percent improvement in the MoCA, from baseline to each follow-up visit, correlated with the percent reduction in sway area dual-task cost at each respective visit ($r^2 = 0.62, P = .005$). No other significant associations between MoCA and dual task outcomes were observed.

### Effects of One tDCS Session

Participants completed the dual task assessment before and after their first tDCS session. Those receiving tDCS, as compared with sham, exhibited greater percent reduction in dual-task cost to postural sway speed ($F = 6.2, P = .03$, Cohen’s $d = 1.08$) and area ($F = 13.3, P = .003$, Cohen’s $d = 1.36$) (Table 3). tDCS did not alter postural sway speed or area within single-task conditions. Instead, tDCS as compared with sham resulted in greater percent reductions to these variables when dual tasking (speed: $F = 5.5, P = .03$, Cohen’s $d = 1.03$; area: $F = 13.2, P = .003$, Cohen’s $d = 1.36$). This single session of tDCS did not influence walking speed within either task condition.

### Relationships Between the Effects of Single and Multiple tDCS Sessions

Participants who exhibited greater reduction in the dual-task costs to sway speed and area following the first tDCS session were more likely to exhibit greater reduction in these outcomes, as well as improvements in MoCA performance, at the 2-week follow-up ($r^2 > 0.60, P = .04$).

### Discussion

This pilot, randomized, sham-controlled trial suggests that a 10-session tDCS intervention with the anode over the left dlPFC and the cathode of the right supraorbital region is feasible and safe for older adults with impairments in gait and executive function. tDCS improved performance on the MoCA within the visuospatial executive function subscore and enhanced various aspects of gait and postural control that were retained for at least 2 weeks. Additionally, the first session of the tDCS intervention induced immediate improvements to dual-task standing and walking performance, and those who exhibited larger improvements following this session also exhibited larger improvements following the entire intervention.

The tDCS intervention improved MoCA performance on questions linked to executive function (ie, short TMT, drawing a cube, drawing a clock). This improvement was not likely due to practice effects, even though the TMT was also administered, as a different version of the MoCA was used at each assessment and improvements were limited to the tDCS group. This result is consistent with and extends multiple studies in healthier, younger cohorts reporting that one session of tDCS with the anode over the left dlPFC improves...
As the current trial focused on very old adults with demonstrated executive dysfunction, it provides preliminary yet promising support that tDCS may also induce lasting improvements in executive function within more vulnerable populations.

Individuals who completed the tDCS intervention improved several aspects of postural control and gait, particularly when standing or walking within dual-task conditions. Baseline dual-task costs to standing and walking outcomes were greater in the current cohort compared with published reports of healthy older adults. The observation that tDCS mitigated dual-task costs to postural sway suggests that the intervention improved participant capacity to recruit available cognitive-motor resources and/or effectively allocate available resources to each task within the dual-task paradigm. Studies employing portable neuroimaging technology (eg, functional near-infrared spectroscopy) are warranted to examine the effects of tDCS on brain activation during normal and dual task standing, in order to better understand tDCS-induced changes in brain function leading to functional improvement.

The tDCS intervention did not induce significant changes in walking speed or TUG performance. It did however result in shorter stride times and less stride time variability when walking while dual tasking. In older adults, these outcomes, especially when dual tasking, are greater in those with previous falls and in those with executive dysfunction. The observation that tDCS with the anode over the left dlPFC and the cathode of the right supraorbital region improved these outcomes supports the involvement of the left dlPFC (and its connected neural networks) in the working memory and set-shifting. As the current trial focused on very old adults with demonstrated executive dysfunction, it provides preliminary yet promising support that tDCS may also induce lasting improvements in executive function within more vulnerable populations.

### Table 3. The Immediate Effects of a 20-Minute Session of tDCS on Standing and Walking With and Without Dual Tasking (Percent Change From Baseline).

<table>
<thead>
<tr>
<th></th>
<th>tDCS</th>
<th>Sham</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Standing postural sway</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single task</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speed</td>
<td>−3 ± 14</td>
<td>−1 ± 18</td>
<td>.89</td>
</tr>
<tr>
<td>Area</td>
<td>4 ± 44</td>
<td>5 ± 12</td>
<td>.49</td>
</tr>
<tr>
<td>Dual task</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speed</td>
<td>−15 ± 21</td>
<td>5 ± 12</td>
<td>.03</td>
</tr>
<tr>
<td>Area</td>
<td>−32 ± 32</td>
<td>20 ± 25</td>
<td>.003</td>
</tr>
<tr>
<td>Dual-task cost</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speed</td>
<td>−14 ± 8</td>
<td>12 ± 17</td>
<td>.003</td>
</tr>
<tr>
<td>Area</td>
<td>−41 ± 14</td>
<td>22 ± 39</td>
<td>.0004</td>
</tr>
<tr>
<td><strong>Walking</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single task</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speed (m/s)</td>
<td>8 ± 3</td>
<td>3 ± 10</td>
<td>.18</td>
</tr>
<tr>
<td>Stride time (s)</td>
<td>−1 ± 4</td>
<td>−2 ± 6</td>
<td>.67</td>
</tr>
<tr>
<td>Variability (COV)</td>
<td>−33 ± 13</td>
<td>−10 ± 16</td>
<td>.12</td>
</tr>
<tr>
<td>Dual task (m/s)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speed</td>
<td>11 ± 9</td>
<td>9 ± 13</td>
<td>.78</td>
</tr>
<tr>
<td>Stride time (s)</td>
<td>−3 ± 4</td>
<td>−2 ± 7</td>
<td>.78</td>
</tr>
<tr>
<td>Variability (COV)</td>
<td>4 ± 20</td>
<td>−3 ± 25</td>
<td>.25</td>
</tr>
<tr>
<td>Dual-task cost (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speed</td>
<td>5 ± 11</td>
<td>3 ± 11</td>
<td>.73</td>
</tr>
<tr>
<td>Stride time (s)</td>
<td>16 ± 16</td>
<td>−7 ± 28</td>
<td>.25</td>
</tr>
<tr>
<td>Variability (COV)</td>
<td>−7 ± 3 2</td>
<td>5 ± 15</td>
<td>.45</td>
</tr>
</tbody>
</table>

Abbreviations: tDCS, transcranial direct current stimulation; COV, coefficient of variation about average stride time.

*Values reflect the mean and standard deviation percent change from baseline values as reported in Table 1. Percent change mean values with a significant intervention main effect (P ≤ .05) are in boldface.
regulation of these important aspects of locomotor control and extends previous work by demonstrating the ability to change behaviors associated with this brain region. All participants completed the dual-task assessment before and after the first tDCS intervention session. Compared with sham, this session of tDCS immediately reduced the dual-task costs to standing postural sway speed and area. These results are consistent with our previous studies in healthy younger and older adults.\textsuperscript{20,30} We also observed that those who demonstrated larger effects on dual-task performance following this single tDCS session exhibited larger improvements in cognitive-motor performance 2 weeks following the entire intervention. We therefore contend that the beneficial effects of tDCS may arise from modulation of frontal-executive systems linked to dynamic components of resource allocation. While this relationship needs to be confirmed, it also suggests that immediate after-effects of tDCS may be used to identify individuals who are most likely to respond favorably to longer interventions.

Our study was limited by a small sample size. Trials with larger samples and longer follow-ups are needed to confirm the observed effects of tDCS on cognitive-motor function. The use of an inactive sham protocol resulted in successful participant blinding to assigned intervention. It is possible that cognitive-motor improvements following tDCS did not arise from modulation of a specific brain region, but rather, a more general effect of stimulation on the brain. As modeled in Figure 2, the electrical field generated by tDCS likely influenced brain function beyond that of the left dIPFC. Future trials should consider comparing the effectiveness of the current tDCS intervention to “high-definition” montages that more focally target the left dIPFC, as well as to active tDCS targeting other brain regions or networks (e.g., sensorimotor cortices). Finally, age-related changes in brain anatomy and function likely influenced electrical current flow and may have contributed to interparticipant variance in intervention effectiveness.\textsuperscript{49} We speculate that “personalized” tDCS administered via an array of electrodes delivering current with parameters derived from modeling of individual magnetic resonance images\textsuperscript{49} will optimize current flow to the desired target and thus, improve the consistency of tDCS-induced benefits. Still, this small yet well-controlled study highlights the potential for tDCS to improve executive function and dual-task performance even in older adults who have deficits in gait and cognitive function.

**Authors’ Note**

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the National Institutes of Health, or other funding sources.

**Declaration of Conflicting Interests**

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Pascual-Leone serves on the scientific advisory boards for Nexstim, Neuronix, Starlab Neuroscience, Neuroelectrics, Axilum Robotics, Magstim Inc, and Neosync and is listed as an inventor on several issued and pending patents on the real-time integration of transcranial magnetic stimulation with electroencephalography and magnetic resonance imaging.

**Funding**

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Catalyst Award from the Falk Medical Research Trust, the Marcus Applebaum Pilot Award, a grant from the U.S.-Israel Binational Science foundation and grants from the National Institute on Aging (R01 AG041785 and R01 AG025037 to Dr Lipsitz, K01 AG044543 to Dr Manor, and T32 AG023480 to Dr Lo). Biostatistical resources were provided by the Boston Claude D. Pepper Older Americans Independence Center (P30-AG013679). Dr Pascual-Leone was partly supported by the Sidney R. Baer Jr. Foundation, the Football Players Health Study at Harvard University, and Harvard Catalyst | The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH, UL1 RR025758). Dr. Lipsitz holds the Irving and Edyth S. Usen and Family Chair in Geriatric Medicine at Hebrew SeniorLife, Boston, Massachusetts. Dr Zhou was supported by the Milstein Medical Asian American Partnership (MMAAP) Foundation.

**ORCID iD**

Rachel Harrison https://orcid.org/0000-0001-9847-4033

**References**


